Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal vaccine-GlaxoSmithKline-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis-Haemophilus influenzae type b infection-meningococcal C disease
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The drug name refers to a combination immunization regimen developed by GSK, consisting of an investigational heptavalent vaccine (GSK2202083A) and a 10-valent pneumococcal conjugate vaccine (Synflorix). GSK2202083A is designed to protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, *Haemophilus influenzae* type b (Hib), and meningococcal C (MenC). Synflorix (GSK1024850A) provides protection against 10 serotypes of *Streptococcus pneumoniae*. This co-administered regimen was evaluated in Phase 2 clinical trials in healthy infants to assess safety and immunogenicity when given as a three-dose primary course. The approach aims to simplify the pediatric vaccination schedule by providing broad protection against eight major childhood diseases in a single visit.
- Brand names
- Synflorix
- Other names
- GSK2202083A + SynflorixDTPa-HBV-IPV/Hib-MenC + PCV10
02
Targets
FHA (Filamentous hemagglutinin)Neisseria meningitidis group C capsular polysaccharideCPS (Streptococcus pneumoniae capsular polysaccharide)HBsAg (Hepatitis B surface antigen)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on pneumococcal vaccine-GlaxoSmithKline-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis-Haemophilus influenzae type b infection-meningococcal C disease.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal vaccine-GlaxoSmithKline-diphtheria-tetanus-pertussis-hepatitis B-poliomyelitis-Haemophilus influenzae type b infection-meningococcal C disease.